CNAT - Merck Doesn't Want To Be Left Out Of The NASH Race Either Uses Option Agreement
Recently, Merck (MRK) expanded an old research collaboration with one of its partners known as NGM Biopharmaceuticals, Inc. (NGM). The newly expanded deal was made to include an option to license a NASH product from the pipeline. This product showed some pretty good preliminary data in treating the disease. The best part of all is that the deal just needed to be amended slightly, and not much cash needed to be added into the mix. Having said that, Merck is gearing up to explore the drug NGM313 in a phase 2